Function and regulation of constitutive protein translation in platelets

Information

  • Research Project
  • 10278179
  • ApplicationId
    10278179
  • Core Project Number
    R01HL159006
  • Full Project Number
    1R01HL159006-01
  • Serial Number
    159006
  • FOA Number
    PA-20-185
  • Sub Project Id
  • Project Start Date
    9/1/2021 - 2 years ago
  • Project End Date
    5/31/2025 - a year from now
  • Program Officer Name
    MOON, KYUNG
  • Budget Start Date
    9/1/2021 - 2 years ago
  • Budget End Date
    5/31/2022 - a year ago
  • Fiscal Year
    2021
  • Support Year
    01
  • Suffix
  • Award Notice Date
    8/27/2021 - 2 years ago

Function and regulation of constitutive protein translation in platelets

Project Summary The goals of this proposal are: 1) to elucidate the molecular signaling of protein translation initiation in circulating human platelets and characterize the plasma growth factor- or hormone-driven pathways, map the regenerating human platelet proteome, and determine the roles of constitutive translation in platelet functional reactivity; 2) to determine the roles of ARGONAUTE2 (AGO2, Ago2 in mice) in platelet mRNA, microRNA (miRNA) and protein expression, platelet reactivity, and the specific roles of platelet miRNA-mediated suppression of translation in hemostasis and thrombotic potential. The studies in this proposal will elucidate essential concepts of the molecular physiology of platelet function. In addition, these studies will have profound implications for two areas of widespread clinical significance: alterations in growth factor/hormone homeostasis, and current use and development of pharmacological inhibitors of translation in disease treatment. Surprisingly little attention has been paid to roles of translation in so-called ?resting? platelets in circulation, following the overall presumption that translation is of limited importance. In prior studies of ?resting? platelet translation, ex vivo platelets were removed from their native plasma environment, and translation steadily came to a halt. We interpret these prior studies to suggest instead that platelets undergo translation constitutively in the presence of plasma, e.g., in circulation, and that this expenditure of molecular resources and cellular energetics is critical for platelet protein homeostasis and functionality. Our strong preliminary data support this hypothesis and we propose a series of innovative approaches to investigate this poorly understood aspect of platelet biology and its functional outcomes. We have shown for the first time that platelets in circulation undergo constitutive translation of a robust proteome due to translation initiation signaling driven by plasma-borne growth factors and hormones, that this process is modulated by platelet miRNAs and AGO2, and that constitutive miRNA-modulated translation in platelets regulates platelet function. We will pursue an array of innovative approaches to test the following hypotheses: Aim 1- 1) ?resting? platelets in circulation are translationally active due to ongoing signaling initiated by plasma growth factors and hormones; 2) constitutive translation driven by plasma growth factors maintains platelet protein homeostasis necessary for hemostatic function; Aim 2 - 1) abundant miRNAs and Ago2-mediated RNA inhibition in platelets modulate constitutive translation driven by plasma growth factors and hormones; 2) Ago2/miRNA-mediated suppression maintains platelets in a reactive state necessary to support hemostasis while limiting thrombosis. Together, the outcomes of these studies will significantly expand our understanding of control of platelet function, hemostasis and thrombosis, as well as implications for platelet reactivity and function in growth factor or hormone imbalance in disease, and potential impacts of clinical translation inhibitors on these processes.

IC Name
NATIONAL HEART, LUNG, AND BLOOD INSTITUTE
  • Activity
    R01
  • Administering IC
    HL
  • Application Type
    1
  • Direct Cost Amount
    250000
  • Indirect Cost Amount
    140000
  • Total Cost
    390000
  • Sub Project Total Cost
  • ARRA Funded
    False
  • CFDA Code
    839
  • Ed Inst. Type
    SCHOOLS OF MEDICINE
  • Funding ICs
    NHLBI:390000\
  • Funding Mechanism
    Non-SBIR/STTR RPGs
  • Study Section
    HTBT
  • Study Section Name
    Hemostasis, Thrombosis, Blood Cells and Transfusion Study Section
  • Organization Name
    THOMAS JEFFERSON UNIVERSITY
  • Organization Department
    INTERNAL MEDICINE/MEDICINE
  • Organization DUNS
    053284659
  • Organization City
    PHILADELPHIA
  • Organization State
    PA
  • Organization Country
    UNITED STATES
  • Organization Zip Code
    191074418
  • Organization District
    UNITED STATES